Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9933420 | 0.84 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL9934235 | 0.79 | UGCG (0.39) | PIK3CGHTR2CMEN1MAPTKMT2A | |
| SCHEMBL9935368 | 0.79 | UGCG (0.39) | PIK3CGHTR2CMEN1MAPTKMT2A | |
| SCHEMBL9933734 | 0.76 | DPP4 (0.47) | CYP3A4DPP4DPP8CNR2 | |
| SCHEMBL9973905 | 0.71 | IDH1 (0.39) | CNR2MEN1MAPTKMT2ALMNA | |
| SCHEMBL9932906 | 0.70 | S100A4 (0.40) | MAPTKMT2ALMNA | |
| SCHEMBL9933485 | 0.70 | S100A4 (0.40) | MAPTKMT2ALMNA | |
| SCHEMBL4226020 | 0.66 | P2RX3 (0.35) | MEN1MAPTKMT2A | |
| SCHEMBL31184230 | 0.65 | PIK3CG (0.33) | PIK3CGMEN1MAPTKMT2A | |
| SCHEMBL31184309 | 0.65 | PIK3CG (0.33) | PIK3CGMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | HARRIS III RALPH NEW (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | P2RX7, P2RX3, P2RX1 | PIK3CG 1523/4885HTR2C 150/4885CYP3A4 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.